454 Life Sciences plans R&D expansion: Surgeons plan test of ReNeuron stem cell therapy;

> 454 Life Sciences is blueprinting a $5 million R&D expansion in Branford, CT. Report

> CombinatoRx has completed its deal to merge with Canada's Neuromed Pharmaceuticals. Story

Bloomberg outlines researchers' plans to put ReNeuron's stem cell therapy to the test in 12 men disabled by a stroke. A neurosurgeon will inject two million stem cells into the brains of the first patient early next year. Story

Pharma News

> The Amgen-Roche patent smackdown is finally finito. A U.S. District Court in Boston ruled that Roche's anemia drug Mircera does in fact infringe Amgen's patents. And the court entered a permanent injunction to keep Roche from selling the drug in the U.S. until mid-2014. Article

> Pharma may be forced to cough up $20 billion more cost cuts in the battle for healthcare reform. Report

> What if pharma threw a party in China but the government refused to come? Well, that's just what might happen as a result of new rules that give domestic companies preference in government purchasing. Article

> When Sanofi-Aventis agreed to buy consumer healthcare specialist Chattem earlier this week, the $1.9 billion deal set industry tongues a-wagging about OTC meds and their importance to pharma sales growth. Report

> The FDA says Vytorin 'unlikely' to boost cancer risk. Article

Vaccine News

> Most of the experts who served on federal review panels for new vaccines in 2007 had conflicts of interest that were either never discovered or never resolved, according to a new report from the inspector general of Health and Human Services. Report

> AstraZeneca's MedImmune is scrambling to retrieve up to about five million doses of swine flu vaccine that has lost at least some of its potency. Item

> Researchers at Duke University have offered up a key insight that could help researchers develop a new AIDS vaccine. Article

And Finally.... The often feared and sometimes deadly infections caused by MRSA--methicillin-resistant Staphylococcus aureus--are now moving out of hospitals and emerging as an even more virulent strain in community settings and on athletic teams. Release

Suggested Articles

Half of patients in an early trial of Allogene's off-the-shelf CAR-T cells for lymphoma who received a higher dose of its antibody ALLO-647 responded.

Takeda is tossing out a Shire pipeline med after it couldn't find a buyer.

Ipsen's new hire arrives at a company reeling from a torrent six months that have crushed hopes for its $1 billion bet on a rare disease drug.